The defendants did not provide scientific evidence to support their claims instead their advertisement contained fake consumer testimonials, according to the Commission.
HCI promoted and sold Rejuvi-Cell, Rejuvi-Sea, and Rejuvi-Stem through telemarketing calls and its websites. The company targeted older consumers across the United States, according to the FTC.
HCI marketed Rejuvi-Cell as a homeopathic oral spray containing human growth hormone. In reality, the product only contained pig growth hormone. The company sold Rejuvi-Sea as capsules containing marine phytoplankton. It marketed Rejuvi-Stem as tablets that enhances, releases, and recruits adult stem cells so they can migrate to parts of the body where needed most. adult stem cells that can migrate to parts of the body where needed most.
According to the Commission, the defendants violated the Telemarketing Sales Rule, which prohibits telemarketers from misrepresenting material aspects of the performance or efficacy of products or services offered for sale. They also violated the FTC Act for making false claims regarding tests and ingredients of their products.
